Abstract: Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin ® ) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed. Keywords: bevacizumab, glioblastoma, glioma, adverse events

Yoshitaka Narita

Therapeutics and Clinical Risk Management

THERAPEUTICS AND CLINICAL RISK MANAGEMENT 是一本经过同行评审的国际临床治疗和风险管理期刊，专注于对所有治疗领域的临床研究、结果、安全性和有效、安全和持续使用药物的计划进行简明快速的报告，所有临床领域的治疗和手术干预。该杂志欢迎提交涵盖原始研究、临床和流行病学研究、评论、指南、专家意见和评论的投稿。该杂志将考虑案例报告，但前提是它们对文献做出了有价值的原创贡献。自 2019 年 3 月 18 日起，治疗学和临床风险管理将不再考虑发表荟萃分析。该杂志不接受研究方案、基于动物或基于细胞系的研究。

Therapeutics and Clinical Risk Management is a peer-reviewed international journal focused on clinical therapy and risk management. The journal aims to provide concise and rapid reports on clinical research, outcomes, safety, and the effective and sustained use of medications across all therapeutic areas. We welcome submissions that include original research, clinical and epidemiological studies, reviews, guidelines, expert opinions, and commentaries. While case reports will be considered, they must provide valuable original contributions to the existing literature. As of March 18, 2019, the journal will no longer consider the publication of meta-analyses. Additionally, we do not accept study protocols or research based on animals or cell lines.

《Therapeutics and Clinical Risk Management》是一本经过同行评审的国际期刊，专注于临床治疗和风险管理。该期刊致力于快速、简明地报告所有治疗领域的临床研究、结果、安全性以及药物的有效性和持续使用。我们欢迎提交涵盖原始研究、临床和流行病学研究、评论、指南、专家意见和评论的稿件。虽然我们会考虑案例报告，但前提是这些报告对现有文献做出了有价值的原创贡献。自2019年3月18日起，本期刊将不再考虑发表荟萃分析。同时，我们不接受研究方案、基于动物或细胞系的研究。

Bevacizumab for glioblastoma

Although the addition of BV to the conventional standard therapy for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time.

Category	Quartile
医学	3
医学, 卫生保健与服务	4

Bevacizumab for glioblastoma

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
HEALTH CARE SCIENCES & SERVICES	2